Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Health Canada approves COVID 19 AstraZeneca vaccine to prevent COVID-19

Written by | 17 Mar 2021

Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19) and a related shot by the Serum Institute of India for use in Canada.

Update on the safety of COVID-19 Vaccine AstraZeneca

Written by | 16 Mar 2021

Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety… read more.

AstraZeneca Pharma India announces marketing approval for Tagrisso (Osimertinib)

Written by | 11 Mar 2021

AstraZeneca Pharma India Limited announced that it has received marketing approval for Tagrisso (Osimertinib) for adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer… read more.

The FDA will convene an Advisory Committee meeting to review the NDA for roxadustat to treat anemia of CKD – AstraZeneca + FIbroGen Inc

Written by | 7 Mar 2021

AstraZeneca and FibroGen, Inc. announced that the FDA informed FibroGen that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new… read more.

OlympiA phase III trial of Lynparza for the treatment of BRCA-mutated high-risk HER2-negative early breast cancer will reported early – AstraZeneca + Merck Inc

Written by | 27 Feb 2021

The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).

WHO gives COVID-19 Vaccine AstraZeneca Emergency Use Listing for COVID-19 – AstraZeneca

Written by | 21 Feb 2021

AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age… read more.

COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials

Written by | 11 Feb 2021

The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.